Gene therapy for ocular diseases

British Journal of Ophthalmology

Volumn 95, Issue 5, 2011, Pages 604-612

  Liu, Melissa M ^a   Tuo, Jingsheng ^a   Chan, Chi Chao ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A4; AGENTS ACTING ON THE EYE; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; C MER PROTO ONCOGENE TYROSINE KINASE; CILIARY NEUROTROPHIC FACTOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GA BINDING PROTEIN; GANCICLOVIR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PERIPHERIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMID DNA; PROTEIN BCL 2; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65KDA; RETINOSCHISIN; RHO FACTOR; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1;

CLINICAL EFFECTIVENESS; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; EXPERIMENTAL MODEL; EYE DISEASE; GENE; GENE REPLACEMENT THERAPY; GENE SILENCING; GENE THERAPY; GLAUCOMA; HUMAN; LEBER CONGENITAL AMAUROSIS; NONHUMAN; OPTIC NERVE ATROPHY; OPTIC NERVE DEGENERATION; PATIENT SAFETY; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN TARGETING; PRPH2 GENE; RETINA GANGLION CELL; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINITIS PIGMENTOSA; RETINOBLASTOMA; RETINOSCHISIS; REVIEW; RNA INTERFERENCE; STARGARDT DISEASE; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; UVEITIS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; EYE DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; OCULAR MOTILITY DISORDERS; RETINAL DISEASES;

EID: 79951869373     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.174912     Document Type: Review

References (104)

1. Friedmann T. A brief history of gene therapy. Nat Genet 1992;2:93-8.
2. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58. (Pubitemid 37272241)
3. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3:477-88. (Pubitemid 37328836)
4. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009;15:23-31.
5. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 2008;15:849-57. (Pubitemid 351712618)
6. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996;2:1028-32. (Pubitemid 26306843)
7. Stieger K, Mendes-Madeira A, Meur GL, et al. Oral administration of doxycycline allows tight control of transgene expression: a key step towards gene therapy of retinal diseases. Gene Ther 2007;14:1668-73. (Pubitemid 350143192)
8. Folliot S, Briot D, Conrath H, et al. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J Gene Med 2003;5:493-501. (Pubitemid 40310392)
9. Dougherty CJ, Smith GW, Dorey CK, et al. Robust hypoxia-selective regulation of a retinal pigment epithelium-specific adeno-associated virus vector. Mol Vis 2008;14:471-80. (Pubitemid 351377319)
10. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15:1022-33. (Pubitemid 39552284)
11. Lamartina S, Cimino M, Roscilli G, et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med 2007;9:862-74. (Pubitemid 47543253)
12. Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006;8:275-85.
13. Molina RP, Ye HQ, Brady J, et al. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct. Hum Gene Ther 2004;15:865-77. (Pubitemid 39244841)
14. Berkowitz R, Ilves H, Lin WY, et al. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J Virol 2001;75:3371-82. (Pubitemid 32225900)
15. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12:348-53. (Pubitemid 43355085)
16. Conley SM, Cai X, Naash MI. Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther 2008;10:456-63.
17. Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006;1:e38.
18. Chalberg TW, Genise HL, Vollrath D, et al. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci 2005;46:2140-6.
19. Kachi S, Oshima Y, Esumi N, et al. Nonviral ocular gene transfer. Gene Ther 2005;12:843-51. (Pubitemid 40753976)
20. Bainbridge JW, Mistry A, De AM, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002;9:320-6. (Pubitemid 34285145)
21. Tuo J, Pang JJ, Cao X, et al. AAV5-mediated sFLT-1 gene therapy ameliorates retinal lesions in Ccl2/Cx3cr1 deficient mice. IOVS 2010:ARVO E-Abstract 4509.
22. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002;6:490-4. (Pubitemid 35214870)
23. Balaggan KS, Binley K, Esapa M, et al. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther 2006;13:1153-65. (Pubitemid 44084074)
24. Igarashi T, Miyake K, Kato K, et al. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 2003;10:219-26. (Pubitemid 36204410)
25. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002;43:1994-2000. (Pubitemid 34587052)
26. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001;188:253-63. (Pubitemid 32622916)
27. Saishin Y, Silva RL, Saishin Y, et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther 2005;16:473-8. (Pubitemid 40647144)
28. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, singleadministration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12:2029-32.
29. Ali RR, Sarra GM, Stephens C, et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000;25:306-10. (Pubitemid 30437318)
30. Schlichtenbrede FC, Smith AJ, Bainbridge JW, et al. Improvement of neuronal visual responses in the superior colliculus in Prph2(Rd2/Rd2) mice following gene therapy. Mol Cell Neurosci 2004;25:103-10. (Pubitemid 38220868)
31. Sarra GM, Stephens C, De AM, et al. Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum Mol Genet 2001;10:2353-61.
32. Schlichtenbrede FC, da CL, Stephens C, et al. Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med 2003;5:757-64. (Pubitemid 40309713)
33. Chadderton N, Millington-Ward S, Palfi A, et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 2009;17:593-9.
34. Jomary C, Vincent KA, Grist J, et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther 1997;4:683-90. (Pubitemid 27343130)
35. Takahashi M, Miyoshi H, Verma IM, et al. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol 1999;73:7812-16. (Pubitemid 29383266)
36. Bennett J, Zeng Y, Bajwa R, et al. Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse. Gene Ther 1998;5:1156-64. (Pubitemid 28448422)
37. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats. Gene Ther 2003;10:1503-11. (Pubitemid 36987144)
38. Lau D, McGee LH, Zhou S, et al. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest Ophthalmol Vis Sci 2000;41:3622-33.
39. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Synergistic neuroprotective effect via simian lentiviral vector-mediated simultaneous gene transfer of human pigment epithelium-derived factor and human fibroblast growth factor-2 in rodent models of retinitis pigmentosa. J Gene Med 2008;10:1273-81.
40. Rex TS. Rescue of sight by gene therapy - closer than it may appear. Ophthalmic Genet 2007;28:127-33. (Pubitemid 47493765)
41. Cayouette M, Behn D, Sendtner M, et al. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci 1998;18:9282-93. (Pubitemid 28512459)
42. Cayouette M, Gravel C. Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene Ther 1997;8:423-30. (Pubitemid 27140545)
43. Liang FQ, Dejneka NS, Cohen DR, et al. AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001;3:241-8. (Pubitemid 32509827)
44. Schlichtenbrede FC, MacNeil A, Bainbridge JW, et al. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther 2003;10:523-7. (Pubitemid 36395269)
45. Vollrath D, Feng W, Duncan JL, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci U S A 2001;98:12584-9. (Pubitemid 33019989)
46. Smith AJ, Schlichtenbrede FC, Tschernutter M, et al. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther 2003;8:188-95. (Pubitemid 37062829)
47. Tschernutter M, Schlichtenbrede FC, Howe S, et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther 2005;12:694-701. (Pubitemid 40561508)
48. Williams ML, Coleman JE, Haire SE, et al. Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med 2006;3:e201.
49. Sun X, Pawlyk B, Xu X, et al. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 2010;17:117-31.
50. Pawlyk BS, Smith AJ, Buch PK, et al. Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 2005;46:3039-45. (Pubitemid 44264286)
51. Pang JJ, Chang B, Kumar A, et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 2006;13:565-72. (Pubitemid 43257624)
52. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med 2006;3:e347.
53. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005;12:1072-82. (Pubitemid 41723041)
54. Le MG, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14:292-303. (Pubitemid 46231923)
55. Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006;17:845-58. (Pubitemid 44681454)
56. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A 2005;102:6177-82. (Pubitemid 40594274)
57. Alexander JJ, Umino Y, Everhart D, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007;13:685-7. (Pubitemid 46889758)
58. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008;118:1955-64. (Pubitemid 351632397)
59. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 2008;15:1311-20.
60. Kjellstrom S, Bush RA, Zeng Y, et al. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 2007;48:3837-45. (Pubitemid 351261125)
61. Takada Y, Vijayasarathy C, Zeng Y, et al. Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery. Invest Ophthalmol Vis Sci 2008;49:3677-86.
62. Park TK, Wu Z, Kjellstrom S, et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009;16:916-26.
63. Janssen A, Min SH, Molday LL, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 2008;16:1010-17. (Pubitemid 351737064)
64. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;44:4357-65. (Pubitemid 37186270)
65. van Adel BA, Kostic C, Deglon N, et al. Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum Gene Ther 2003;14:103-15. (Pubitemid 36418815)
66. Ishikawa H, Takano M, Matsumoto N, et al. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 2005;12:289-98. (Pubitemid 40310131)
67. De KY, Thillaye-Goldenberg B, Naud MC, et al. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002;130:212-23.
68. Broderick CA, Smith AJ, Balaggan KS, et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther 2005;12:369-73. (Pubitemid 41025109)
69. Smith JR, Verwaerde C, Rolling F, et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 2005;16:1037-46. (Pubitemid 41324563)
70. Tsai ML, Horng CT, Chen SL, et al. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis 2009;15:1542-52.
71. Shih CS, Laurie N, Holzmacher J, et al. AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med 2009;11:43-52.
72. Hurwitz MY, Marcus KT, Chevez-Barrios P, et al. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther 1999;10:441-8. (Pubitemid 29097322)
73. Mancuso K, Hauswirth WW, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature 2009;461:784-7.
74. Yoon KC, Bae JA, Park HJ, et al. Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model. Gene Ther 2009;16:973-81.
75. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000;184:301-10. (Pubitemid 30625492)
76. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705-9. (Pubitemid 23347111)
77. Bainbridge JW, Mistry AR, Thrasher AJ, et al. Gene therapy for ocular angiogenesis. Clin Sci (Lond) 2003;104:561-75. (Pubitemid 36713846)
78. Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 2007;19:75-9.
79. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76. (Pubitemid 43262032)
80. Perrault I, Rozet JM, Gerber S, et al. Spectrum of retGC1 mutations in Leber's congenital amaurosis. Eur J Hum Genet 2000;8:578-82. (Pubitemid 30639363)
81. Moiseyev G, Chen Y, Takahashi Y, et al. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005;102:12413-18. (Pubitemid 41266373)
82. den Hollander AI, Roepman R, Koenekoop RK, et al. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008;27:391-419.
83. Jacobson SG, Acland GM, Aguirre GD, et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006;13:1074-84. (Pubitemid 43796158)
84. Nusinowitz S, Ridder WH III, Pang JJ, et al. Cortical visual function in the rd12 mouse model of Leber Congenital Amarousis (LCA) after gene replacement therapy to restore retinal function. Vision Res 2006;46:3926-34. (Pubitemid 44374620)
85. Chang GQ, Hao Y, Wong F. Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron 1993;11:595-605. (Pubitemid 23321770)
86. Rex TS, Allocca M, Domenici L, et al. Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther 2004;10:855-61. (Pubitemid 39419912)
87. Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res 1993;602:304-17. (Pubitemid 23053202)
88. Barraza RA, Rasmussen CA, Loewen N, et al. Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates. Hum Gene Ther 2009;20:191-200.
89. Liu X, Rasmussen CA, Gabelt BT, et al. Gene therapy targeting glaucoma: where are we? Surv Ophthalmol 2009;54:472-86.
90. Huang Q, Liu XZ, Kang CS, et al. The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells. Cancer Gene Ther 2010;17:192-202.
91. Wang ZX, Bian HB, Yang JS, et al. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer. Cancer Biol Ther 2009;8:1480-8.
92. Xu F, Li S, Li XL, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009;16:723-30.
93. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye (Lond) 2003;17:906-11. (Pubitemid 37541043)
94. Andrawiss M, Maron A, Beltran W, et al. Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma. J Gene Med 2001;3:228-39. (Pubitemid 33684771)
95. Martin KR, Quigley HA. Gene therapy for optic nerve disease. Eye (Lond) 2004;18:1049-55. (Pubitemid 39591786)
96. Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009;16:10-16.
97. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9. (Pubitemid 351724452)
98. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008;105:15112-17.
99. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8. (Pubitemid 351724453)
100. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20:999-1004.
101. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-50.
102. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605.
103. Chévez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005;23:7927-35. (Pubitemid 46657392)
104. Ji X, Zhang J, Cheng L, et al. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 2009;89:193-9.